The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 51 results:
Author Title Type [ Year(Asc)]
Filters: Keyword is Fatty Liver  [Clear All Filters]
2017
Kountouras, J., Polyzos S. A., Katsinelos P., Doulberis M., Zavos C., Kazakos E., et al. (2017).  Letter: Helicobacter pylori in lean and obese patients with non-alcoholic fatty liver disease.. Aliment Pharmacol Ther. 46(6), 637-638.
Kountouras, J., Polyzos S. A., Kapetanakis N., Katsinelos P., Nikolopoulos P., Stogianni A., et al. (2017).  Letter: Helicobacter pylori-related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia.. Aliment Pharmacol Ther. 45(4), 576-577.
Athyros, V. G., Alexandrides T. K., Bilianou H., Cholongitas E., Doumas M., Ganotakis E. S., et al. (2017).  The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.. Metabolism. 71, 17-32.
2016
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Triantafyllou G. Α., & Mantzoros C. S. (2016).  Activin A and follistatin in patients with nonalcoholic fatty liver disease.. Metabolism. 65(10), 1550-8.
Levelt, E., Pavlides M., Banerjee R., Mahmod M., Kelly C., Sellwood J., et al. (2016).  Ectopic and Visceral Fat Deposition in Lean and Obese Patients With Type 2 Diabetes.. J Am Coll Cardiol. 68(1), 53-63.
Polyzos, S. A., & Kountouras J. (2016).  Homocysteine in nonalcoholic steatohepatitis: A reply.. Eur J Intern Med. 35, e40-e41.
Polyzos, S. A., & Mantzoros C. S. (2016).  Nonalcoholic fatty future disease.. Metabolism. 65(8), 1007-16.
2014
Polyzos, S. A., Kountouras J., Zavos C., & Deretzi G. (2014).  Helicobacter pylori infection, insulin resistance and nonalcoholic fatty liver disease.. Med Hypotheses. 82(6), 795.
Kountouras, J., Polyzos S. A., Zavos C., Deretzi G., Kountouras C., Vardaka E., et al. (2014).  Helicobacter pylori might contribute to nonalcoholic fatty liver disease-related cardiovascular events by releasing prothrombotic and proinflammatory factors.. Hepatology. 60(4), 1450-1.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Geladari E. V., & Mantzoros C. S. (2014).  Irisin in patients with nonalcoholic fatty liver disease.. Metabolism. 63(2), 207-17.
Polyzos, S. A., & Mantzoros C. S. (2014).  Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease.. Metabolism. 63(2), 161-7.
Polyzos, S. A., Goulis D. G., Kountouras J., Mintziori G., Chatzis P., Papadakis E., et al. (2014).  Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis.. Hormones (Athens). 13(4), 519-31.
2013
Polyzos, S. A., Kountouras J., Papatheodorou A., Katsiki E., Patsiaoura K., Zafeiriadou E., et al. (2013).  Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index.. Ann Hepatol. 12(5), 749-57.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients.. Curr Med Res Opin. 29(7), 791-2.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease.. Expert Opin Ther Targets. 17(7), 861-2.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2013).  Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".. Dig Liver Dis. 45(1), 82-3.
Polyzos, S. A., Kountouras J., Papatheodorou A., Patsiaoura K., Katsiki E., Zafeiriadou E., et al. (2013).  Helicobacter pylori infection in patients with nonalcoholic fatty liver disease.. Metabolism. 62(1), 121-6.
Hall, A. R., Dhillon A. P., Green A. C., Ferrell L., Crawford J. M., Alves V., et al. (2013).  Hepatic steatosis estimated microscopically versus digital image analysis.. Liver Int. 33(6), 926-35.
Athyros, V. G., Tziomalos K., Katsiki N., Gossios T. D., Giouleme O., Anagnostis P., et al. (2013).  The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study.. Curr Vasc Pharmacol. 11(5), 779-84.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Nonalcoholic fatty liver disease and severity of cardiovascular disease manifestations.. Angiology. 64(8), 572-5.
Polyzos, S. A., Kountouras J., Slavakis A., Zafeiriadou E., Patsiaoura K., Katsiki E., et al. (2013).  A novel noninvasive index for nonalcoholic steatohepatitis: a pilot study.. Biomarkers. 18(7), 607-13.
Polyzos, S. A., & Kountouras J. (2013).  Serum alpha-fetoprotein in patients with nonalcoholic fatty liver disease.. Eur Rev Med Pharmacol Sci. 17(17), 2411-2.
Polyzos, S. A., Kountouras J., Romiopoulos I., & Polymerou V. (2013).  Serum visfatin in nonalcoholic fatty liver disease.. Ann Hepatol. 13(1), 150-1.
Polyzos, S. A., Kountouras J., Tsatsoulis A., Zafeiriadou E., Katsiki E., Patsiaoura K., et al. (2013).  Sex steroids and sex hormone-binding globulin in postmenopausal women with nonalcoholic fatty liver disease.. Hormones (Athens). 12(3), 405-16.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2013).  Statins and nonalcoholic fatty liver disease: a bright future?. Expert Opin Investig Drugs. 22(9), 1089-93.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.